Tetraphase Pharmaceu (TTPH) Stock Price, Quote, News and Overview
NASDAQ:TTPH - Nasdaq -
TTPH Quote, Performance and Key Statistics
2.2
-0.08 (-3.51%)
The current stock price of TTPH is 2.2 null. In the past month the price decreased by -14.73%. In the past year, price decreased by -68.12%.
About TTPH
Company Profile
Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company's product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts.
Company Info
Tetraphase Pharmaceu
480 ARSENAL WAY
WATERTOWN MA 02472
CEO: Larry Edwards
Phone: 617-715-3600
Tetraphase Pharmaceu / TTPH FAQ
What is the stock price of Tetraphase Pharmaceu today?
The current stock price of TTPH is 2.2 null. The price decreased by -3.51% in the last trading session.
What is the ticker symbol for Tetraphase Pharmaceu stock?
The exchange symbol of Tetraphase Pharmaceu is TTPH and it is listed on the Nasdaq exchange.
On which exchange is TTPH stock listed?
TTPH stock is listed on the Nasdaq exchange.
What is Tetraphase Pharmaceu worth?
Tetraphase Pharmaceu (TTPH) has a market capitalization of 15.98M null. This makes TTPH a Nano Cap stock.
What are the support and resistance levels for Tetraphase Pharmaceu (TTPH) stock?
Tetraphase Pharmaceu (TTPH) has a resistance level at 2.39. Check the full technical report for a detailed analysis of TTPH support and resistance levels.
Should I buy Tetraphase Pharmaceu (TTPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TTPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TTPH, evaluating the profitability, health, valuation and growth aspects
- Tetraphase Pharmaceu (TTPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Tetraphase Pharmaceu (TTPH) Sales and EPS estimates to see what analysts future expectations are.
- Tetraphase Pharmaceu (TTPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Tetraphase Pharmaceu (TTPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- Tetraphase Pharmaceu (TTPH) Stock Chart to make your own analysis
- Tetraphase Pharmaceu (TTPH) Latest news and press-releases to stay up to date.
Does Tetraphase Pharmaceu (TTPH) stock pay dividends?
TTPH does not pay a dividend.
What is the Price/Earnings (PE) ratio of Tetraphase Pharmaceu (TTPH)?
Tetraphase Pharmaceu (TTPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.46).
TTPH Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to TTPH. When comparing the yearly performance of all stocks, TTPH is a bad performer in the overall market: 64.88% of all stocks are doing better.
TTPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TTPH. TTPH has a bad profitability rating. Also its financial health evaluation is rather negative.
TTPH Financial Highlights
Over the last trailing twelve months TTPH reported a non-GAAP Earnings per Share(EPS) of -18.46. The EPS decreased by -126.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -798.18% | ||
| ROA | -167.91% | ||
| ROE | N/A | ||
| Debt/Equity | 0.06 |
TTPH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 40% to TTPH. The Buy consensus is the average rating of analysts ratings from 2 analysts.